enGene (ENGN) Stock Price, News & Analysis

Company Overview

enGene is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

Key Stats

• Today's Range: $1.85 to $1.93
• 50-Day Range: $1.44 to $8.85
• 52-Week Range: $1.40 to $12.25
• Volume: 1.35 million shs
• Average Volume: 1.09 million shs
• Market Capitalization: $126.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.05
• Consensus Rating: Hold

enGene Stock Analysis - MarketRank™

enGene scored higher than 78% of companies evaluated by MarketBeat, and ranked 141st out of 853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

enGene has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 4 buy ratings, 8 hold ratings, and 2 sell ratings.

Upside Potential

enGene has a consensus price target of $11.05, representing about 482.9% upside from its current price of $1.90.

Amount of Analyst Coverage

enGene has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for enGene are expected to grow in the coming year, from ($1.84) to ($1.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of enGene is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of enGene is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

enGene has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.90% of the float of enGene has been sold short.

Short Interest Ratio / Days to Cover

enGene has a short interest ratio ("days to cover") of 1.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enGene has recently decreased by 17.87%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

enGene does not currently pay a dividend.

Dividend Growth

enGene does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.45

News Sentiment

enGene has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for enGene this week, compared to 10 articles on an average week.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, enGene insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.50% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/15/2026
• Today: 7/15/2026
• Next Earnings (Estimated): 9/14/2026
• Fiscal Year End: 10/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENGN
• Previous Symbol: NASDAQ:ENGN
• CIK: 1980845
• Web: www.engene.com
• Phone: 302-273-0765
• Fax: N/A
• Employees: 31
• Year Founded: 1999

Price Target and Rating

• Average Price Target for enGene: $11.05
• High Price Target: $30.00
• Low Price Target: $2.00
• Potential Upside/Downside: +482.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$117.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.06%
• Return on Assets: -45.64%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 12.57
• Quick Ratio: 12.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.60 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 66,990,000
• Free Float: 59,952,000
• Market Cap: $126.95 million
• Optionable: N/A
• Beta: -0.28